Response to taxanes in triple negative breast cancer
- 4 March 2008
- journal article
- letter
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 63 (1), 189
- https://doi.org/10.1007/s00280-008-0717-7
Abstract
No abstract availableKeywords
This publication has 2 references indexed in Scilit:
- Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxelCancer Chemotherapy and Pharmacology, 2007
- HER2 and Response to Paclitaxel in Node-Positive Breast CancerThe New England Journal of Medicine, 2007